Despite its efficacy as an immunotherapy, IFN-α is strongly associated with the onset of neuropsychiatric symptoms, including anxiety, sleep alterations, fatigue and depressive symptomatology in 30–50% of patients (Musselman et al.2001; Hauser et al.2002; Schaefer et al.2002). This evidence concerns the gene IFNA1 and Anxiety.